BICO Group swings to profit as AI drug discovery fuels lab automation demand

BICO turns profitable on lab automation thesis

BICO Group AB, the Stockholm-listed life sciences automation company, reported a sharp profitability turnaround in its second quarter 2026 results, posting adjusted EBITDA margin of 6% compared to negative 15% in the year-earlier period. The company's shares jumped more than 13% in pre-market trading following the August 19 announcement, according to details first reported by Investing.com.

The Swedish firm reported net sales of SEK 336 million, representing 7% organic growth in local currencies and 4% on a reported basis. While top-line expansion remained modest, the company delivered adjusted EBITDA of SEK 20 million—a 21-percentage-point margin improvement year-over-year. Gross margin expanded to 59% from 44%, driven by favorable product mix and increased direct sales.

Operating expenses declined 7% as restructuring initiatives took effect. The company moved from net debt of SEK 877 million to a net cash position of SEK 207 million during CEO Maria Forss's tenure, which ends August 31. Anders Fogelberg, who joined BICO in 2024 as Chief Commercial Officer, will succeed her.

Why it matters

BICO's results offer an early indicator of how AI adoption in pharmaceutical research may reshape demand for physical laboratory infrastructure. If the company's thesis proves correct—that AI-generated drug candidates create validation bottlenecks in wet labs rather than reduce experimental workloads—automation equipment suppliers could see sustained demand growth even as software handles more discovery work. The margin expansion also demonstrates that life sciences tooling companies can achieve profitability despite volatile project-based revenue, a concern that has weighed on the sector.

Positioning at the AI-lab intersection

BICO's investor presentation emphasized its strategic positioning at what it calls "the critical layer" between AI hypothesis generation and validated experimental evidence. The company argues that as artificial intelligence accelerates drug candidate identification, the wet lab becomes the constraint that converts computational predictions into proven results.

"More AI-driven candidates mean more experiments, not fewer," the presentation stated. "AI acceleration shifts the bottleneck to the wet lab."

The company's portfolio spans molecular biology, drug discovery, and bioprocessing workflows through brands including CELLENION, SCIENION, BIOSERO, and ECHO. BICO reports more than 53,600 instruments installed across 65-plus countries, with products in over 3,500 laboratories including the world's top 20 pharmaceutical companies.

Product innovation and mixed market signals

BICO showcased several product launches during the presentation. The AI-Powered Confluency feature for ECHO's Rebel and Revolve systems transforms cell culture assessment from subjective visual inspection into quantitative measurement, reducing scientist-to-scientist variation from ±15 percentage points to instant, objective metrics. The G.PURE Gen 2 introduces tipless DNA cleanup, potentially saving mid-sized laboratories 300,000 tips annually while reducing cleanup time from 20 minutes to 2 minutes.

Consumables grew 10% year-over-year, and benchtop instruments performed well. The company noted gradual market recovery in Europe and Asia, though longer lead times persist for larger automation investments, particularly in North America where academic funding pressures continue.

Management declined to provide specific financial guidance, citing seasonal patterns where the first half typically underperforms the second half due to customer budget cycles. The company expects SEK 30 million in annualized savings from R&D consolidation in the second half of 2026.

The financial results and strategic positioning were detailed in BICO Group's Q2 2026 earnings presentation published by Investing.com.